AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01553318
Drug: Ketotifen
RxNorm normalized name: Ketotifen
DrugBank: Ketotifen (DB00920)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After meeting the full eligibility requirement, participants will be randomized. From week 1 to 2, subjects will receive either ketotifen 1 mg by mouth, twice a day or the equivalent placebo. Thereafter, subjects will take ketotifen to 2 mg by mouth twice a day or the equivalent placebo.
Trial: NCT00685945
Drug: Control (bradykinin)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Graded doses of bradykinin (Clinalfa AG, Läufelfingen, Switzerland) will be infused at 50, 100, and 200ng/min. Each dose will be infused for 5 minutes and FBF will measured during the last 2 minutes of infusion. Arterial and venous blood samples will be obtained for measurement of net t-PA release after each dose.
Trial: NCT00685945
Drug: L-NMMA + bradykinin
RxNorm normalized name: L-NMMA
DrugBank: Bradykinin (DB12126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thirty minutes after administration of bradykinin a continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be started started. While continuing the infusion of L-NMMA, baseline measurements and infusion of bradykinin will be repeated.
Trial: NCT00685945
Drug: Isosorbide + L-NMMA + bradykinin
RxNorm normalized name: L-NMMA
DrugBank: Isosorbide (DB09401)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Following the second bradykinin infusion, 12 subjects will receive 5mg isosorbide dinitrate (an exogenous NO donor; Major Pharmaceuticals Inc, Livonia MI). Sixty minutes after the administration of isosorbide the continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be restarted and baseline measurements and bradykinin infusion will be repeated.
Trial: NCT00685945
Drug: Sildenafil + L-NMMA + bradykinin
RxNorm normalized name: L-NMMA
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Following the second bradykinin infusion, 12 subjects will receive 50mg sildenafil (phosphodiesterase type 5 (PDE5) inhibitor to increase cGMP without increasing NO; Pfizer, NY). Sixty minutes after the administration of sildenafil the continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be restarted and baseline measurements and bradykinin infusion will be repeated.
Trial: NCT01492374
Drug: BMS-241027
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous (IV), 0.003 mg/kg, Once Weekly, 9 weeks
Trial: NCT01492374
Drug: BMS-241027
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous (IV), 0.01 mg/kg, Once Weekly, 9 weeks
Trial: NCT01492374
Drug: BMS-241027
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous (IV), 0.03 mg/kg, Once Weekly, 9 weeks
Trial: NCT02489786
Drug: patients take 0.25 mg of digoxin daily except friday
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01120015
Drug: diacerein
RxNorm normalized name: diacerein
DrugBank: Diacerein (DB11994)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac sodium 75mg sustained release tablet once daily was given to both groups for 3 months. Capsule diacerein 50mg in study group and matched placebo in control group were given once daily for first month and twice daily for next two months with the main meals.
Trial: NCT06683404
Drug: Bleomycin
RxNorm normalized name: Bleomycin
DrugBank: Bleomycin (DB00290)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electrochemotherapy (ECT) is characterized by the association between the administration of a chemotherapic agent (Bleomycin) with the temporary raise of permeability of the cellular membrane
Trial: NCT00685204
Drug: Milataxel
RxNorm normalized name: Milataxel
DrugBank: Milataxel (DB12334)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milataxel is a liquid that is dosed orally at 60 mg/m2 on Day 1 of a 21 day cycle. If no toxicities of greater than Grade 1 severity occur, patients will receive 75 mg/m2 for the second and subsequent cycles.
Trial: NCT00434174
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: RAD001 will be supplied by Novartis as tablets in 3 different dosage strengths, 2.5, 5 and 10 mg. All proposed dose levels in this study can be given as a combination of these dose strengths.~Daily doses of 2.5, 5, 7.5 and 10 mg of RAD001 will be given alongside the standard 21-day cycle of pemetrexed.
Trial: NCT00434174
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed was supplied to the sites in 500 mg/m2 was administered on Day 1 of each cycle as a 10-minute continuous i.v. infusion in 100mL normal saline
Trial: NCT02489786
Drug: patients take 0.25 mg of digoxin daily except thursday and friday
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02489786
Drug: patients take 0.125 mg of digoxin daily
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02489786
Drug: digoxin dose is calculated using Jusko-Koup method and given daily
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03496545
Drug: Bromocriptine 5 MG
RxNorm normalized name: bromocriptine 5 MG
DrugBank: Bromocriptine (DB01200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bromocriptine 5 mg every 4 hours PO/NG/FT
Trial: NCT00832572
Drug: Ranolazine
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranolazine ER tablet administered orally for 6 weeks (500 mg twice a day for 3 weeks, followed by either 500 mg or 1000 mg twice a day for 3 weeks).
Trial: NCT02994225
Drug: Indocyanine Green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous injection (1 ml) of the indocyanine green into the ipsilateral upper extremity 10 min before the surgery.~Near Infra-red images acquisition is performed during surgery
Trial: NCT00209573
Drug: fospropofol disodium
RxNorm normalized name: Fospropofol disodium
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02919319
Drug: ACT-541468 (Formulation A)
RxNorm normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hard gelatin capsules for oral administration formulated at strengths of 5 mg, 25 mg and 100 mg
Trial: NCT02919319
Drug: ACT-541468 (Formulation B)
RxNorm normalized name: Hep B, unspecified formulation
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Soft gelatin capsules for oral administration formulated at the strength of 25 mg
Trial: NCT02919319
Drug: 14C-labeled ACT-541468
RxNorm normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tracer at a nominal dose of 250 nCi (corresponding to 2.02 µg ACT-541468) administered either orally or intravenously
Trial: NCT01746043
Drug: Armodafinil
RxNorm normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg by mouth once a day for 6 weeks.
Trial: NCT00379522
Drug: Vasopressin
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 minutes after standard shock treatment 10 IU arginine vasopressin will be injected; if shock persists for 5 minutes, another 10 IU arginine vasopressin will be injected; after 5 minutes persisting shock, the last 10 IU arginine vasopressin will be injected; Total duration: approx. 15 minutes; Dose per intravenous injection: 10 IU; max. dose: 30 IU arginine vasopressin
Trial: NCT00150579
Drug: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02049814
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin tablets
Trial: NCT02049814
Drug: Voglibose
RxNorm normalized name: Voglibose
DrugBank: Voglibose (DB04878)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Voglibose tablets
Trial: NCT02049814
Drug: Acarbose
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose tablets
Trial: NCT02084732
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: drug
Trial: NCT01888445
Drug: roxadustat
RxNorm normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: oral
Trial: NCT01888445
Drug: darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iv
Trial: NCT02112630
Drug: P-IFN alfa 2a
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: P-IFN alfa 2b 0.75 mcg/kg/week
Trial: NCT02112630
Drug: P-IFN alfa 2b
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: P-IFN alfa 2a 135 mcg/kg/week
Trial: NCT02112630
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg PO once daily or 200 mg PO three times a week
Trial: NCT02112630
Drug: Boceprevir
RxNorm normalized name: Boceprevir
DrugBank: Boceprevir (DB08873)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 800 mg PO three times daily starting at week 4
Trial: NCT02857946
Drug: Prevaglip (linagliptin)
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 tablet contains 5 mg linagliptin
Trial: NCT02857946
Drug: Trajenta (linagliptin)
RxNorm normalized name: Tradjenta
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 tablet contains 5 mg linagliptin
Trial: NCT03425084
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study was designed as an open, non-controlled drug trial, with scientists and participants blinded to the patients OCT1 status. Morphine will be given as a single dosis (0,15 mg/kg) at the end of the Surgery and later as boluses of 0,04mg/kg administrated by patient-controlled analgesia, (PCA). Blood samples with drug concentrations will be used to determine a difference in morphine AUC due to the patients OCT1 status. Questionnaire answers will be used to determine the effect of morphine due to the patients OCT1 status
Trial: NCT00092625
Drug: MK0653, ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00092625
Drug: Comparator: ezetimibe, placebo
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00502970
Drug: 16 weeks Interferon Tiw with Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 16 weeks Interferon Tiw
Trial: NCT00502970
Drug: 24 weeks Interferon
RxNorm normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 weeks Interferon Tiw with Ribavirin
Trial: NCT02674958
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 325mg bolus followed by 162mg daily until day 7 post alcohol septal ablation
Trial: NCT04042688
Drug: intraarticular administration of tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraarticular administration with concentration of 30mg/mL was selected. The operation room nurses prepared 3g tranexamic acid in 100 mL of saline solution during operation. After finishing surgical wound suture and orthopaedic surgeons related to this study left operation room, the orthopaedic residents who were not involved in the postoperative evaluation administered tranexamic acid solution through suprapatellar pouch before tourniquet release in patients in the treatment group. The control group did not receive any solution. intraarticular drain was not inserted in all patients.
Trial: NCT00006178
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00006178
Drug: Thymoglobulin
RxNorm normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00184548
Drug: eptacog alfa (activated)
RxNorm normalized name: Eptacog alfa (activated)
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Sterile, freeze-dried powder in single-use vials to be reconstituted with sterile water for injection.~Three doses of 200, 100 and 100 mcg/kg to be administered bolus i.v. (intravenous) over approx. three hours.
Trial: NCT04644705
Drug: Niclosamide
RxNorm normalized name: niclosamide
DrugBank: Niclosamide (DB06803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Niclosamide will be applied in various dosage steps, galenic preparations and in combination with camostat
Trial: NCT02078440
Drug: Bromocriptine mesylate
RxNorm normalized name: Bromocriptine Mesylate
DrugBank: Bromocriptine (DB01200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cycloset (bromocriptine mesylate quick release) 0.8 mg tablets, weight adjusted 1.6 mg- 4.8 mg
Trial: NCT03732482
Drug: Temozolomide capsules
RxNorm normalized name: Temozolomide Capsules
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide capsules(Jiangsu tasly diyi pharmaceutical Co.,Ltd) Oral Temozolomide capsules 75mg/m2 begins on day 1 and continues until completion of radiotherapy.
Trial: NCT00669565
Drug: Bavituximab
RxNorm normalized name: Bavituximab
DrugBank: Bavituximab (DB05136)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive weekly bavituximab at a dose of 3 mg/kg until disease progression, and carboplatin at a dose of AUC = 2 and paclitaxel 100 mg/m2 on days 1, 8, and 15 of a 28-day cycle for up to 6 cycles.
Trial: NCT04089904
Drug: Pembrolizumab Injection
RxNorm normalized name: pembrolizumab Injection
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive 3 cycles of pembrolizumab at 200mg intravenously on day 1 of a 3 week cycle. After 3 cycles the patients will undergo surgery
Trial: NCT01827267
Drug: neratinib
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01827267
Drug: temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00464451
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine 3 micrograms per kilogram per os; subsequent dose of 1 microgram per kilogram per os if necessary to treat inadequate sedation 30 minutes following initial dosing.
Trial: NCT00464451
Drug: Chloral hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloral hydrate 75 milligrams per kilogram per os; subsequent dose of 25 milligrams per kilogram per os if necessary to treat inadequate sedation 30 minutes following initial dosing.
Trial: NCT02942602
Drug: Atorvastatin 20 mg
RxNorm normalized name: atorvastatin 20 MG
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
Trial: NCT02942602
Drug: Cholestyramine 8 g
DrugBank: Cholestyramine (DB01432)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
Trial: NCT02942602
Drug: Omega-3 2g
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
Trial: NCT02942602
Drug: Concurrent with Atorvastatin 5 mg + Ezetimibe 10 mg
RxNorm normalized name: atorvastatin / ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
Trial: NCT01809301
Drug: Niaspan
RxNorm normalized name: Niaspan
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01732640
Drug: Afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib will be supplied as film-coated tablets. Available dosage strengths will be 20, 30, or 40 mg. Tablets will be supplied in HDPE, child-resistant, tamper-evident bottles.
Trial: NCT01732640
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction chemotherapy: 175 mg/m2 day 1 every 21 days for 2 cycles (IV infusion as per institutional standard).
Trial: NCT01732640
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin is available as a sterile lyophilized powder in single-dose vials containing 50 mg, 150 mg, or 450 mg of carboplatin. Each vial contains equal parts by weight of carboplatin and mannitol. Commercial supplies of carboplatin will be used in this trial.
Trial: NCT01732640
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy: 40 mg/m2 once weekly for 7 cycles (IV infusion as per institutional standard).
Trial: NCT00005855
Drug: carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00005855
Drug: efaproxiral
RxNorm normalized name: EFAPROXIRAL
DrugBank: Efaproxiral (DB08486)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00464646
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both Cohorts: Epirubicin 90 mg/m2 IV every 21 days x 4 cycles
Trial: NCT03456804
Drug: ESK981
RxNorm normalized name: ESK981
DrugBank: ESK981 (DB18155)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with ESK981 for patients with metastatic castrate resistant prostate cancer
Trial: NCT04535869
Drug: Sofosbuvir 400 MG plus Daclatasvir 200mg
RxNorm normalized name: sofosbuvir 400 MG
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This group which receive sofosbuvir and daclatasvir for 14 days plus standard therapy
Trial: NCT02439814
Drug: Pregnenolone
RxNorm normalized name: Pregnenolone
DrugBank: Pregnenolone (DB02789)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregnenolone is a steroid that occurs naturally in the body, and early studies have shown that pregnenolone may block the effects of marijuana intoxication
Trial: NCT02695550
Drug: CT-707
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00464646
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both Cohorts: Docetaxel 100 mg/m2 IV on Day 1 every 21 days x 4 cycles
Trial: NCT00464646
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cohort A: Pre-op therapy - 4 mg/kg IV first dose, then subsequent doses at 2 mg/kg IV weekly (16+ weeks) until 1-7 days prior to surgery. Post-operative therapy (beginning no sooner than 28 days after surgery and continuing every 3 weeks x 13 doses) - 8 mg/kg IV first post-op dose, then subsequent doses at 6 mg/kg IV~Cohort B: 4 mg/kg IV first dose, then subsequent doses at 2 mg/kg IV weekly on days 1, 8, and 15. Three (3) weeks after last dose of docetaxel, 6 mg/kg IV and continuing every 3 weeks x 13 doses
Trial: NCT00464646
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cohort A: Cycles 1-4, 15 mg/kg IV on day 1 of cycle 4 only; Cycles 5-7, 15 mg/kg IV on day 1 every 21 days x 3 cycles; post-operative therapy (beginning no sooner than 28 days after surgery), 15 mg/kg IV every 3 weeks x 13 doses~Cohort B: Cycles 5-8, 15 mg/kg IV on day 1 every 21 days x 4 cycles; beginning 3 weeks after last dose of docetaxel, 15 mg/kg IV every 3 weeks x 13 doses
Trial: NCT01681680
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will be given an oral dose of metformin once per day for two days.
Trial: NCT00170625
Drug: Hycamtin
RxNorm normalized name: Hycamtin
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topotecan: 1,0 mg/m²/d, day 1-3; q21d Carboplatin: AUC 5 on day 3 after Topotecan, q21d
Trial: NCT01294696
Drug: Standard of care for treatment of osteoarthritis (OA) of knee(s)
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants will be treated according to standard medical guidelines or usual clinical practice standards of the investigating physician.
Trial: NCT01265745
Drug: Normal Saline for Injection
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equivalent amounts to subjects weight, once over 120 minutes
Trial: NCT02953210
Drug: dexter ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: multimodal anesthesia without opioids ketamine as induction drug